Abstract
Birth defects are not a rare phenomenon, and, in most cases, are not related to environmental agents. A baseline risk for malformation of 1–3% is commonly used as a reference frame for evaluating the teratogenic risk of environmental exposures. Environmental factors that have a teratogenic potential include drugs, chemicals, infections, and physical factors such as ionizing radiation. Most environmental agents were not found to have teratogenic potential, and among the drugs that were proven to be teratogenic only few, such as thalidomide and systemic retinoids, exhibit increased risk for malformation of above 20% when exposure occurred in the sensitive period. Despite the fact that only a handful of drugs and other exposures have proven to be teratogenic, women, and in many cases health providers as well, tend to overestimate teratogenic risk. In many cases, overestimation of risk may cause women to discontinue essential medications or alternatively to terminate wanted pregnancies. Ultrasound can detect a large number of structural anomalies, including many of those reported to be secondary to exposure to potentially teratogenic agents. Therefore, teratogen risk counseling needs to promote evidence-based rather than fear-based decision-making.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Notes
- 1.
Named after the city of Minamata in Japan where, in 1956, methylmercury was released in the industrial wastewater from a chemical factory that resulted in mercury poisoning and cat, dog, pig and human deaths as well as fetal malformations.
References
Moore KL, Persaud TVN, Torchia MG. The developing human: clinically oriented embryology. 8th ed. Philadelphia, PA: Saunders/Elsevier; 2008. p. xiv, 522 p.
Koren G, Pastuszak A, Ito S. Drugs in pregnancy. N Engl J Med. 1998;338(16):1128–37. Epub 1998/04/17.
Heinonen OP, Slone D, Shapiro S. Birth defects and drugs in pregnancy. Littleton, MA: Publishing Sciences Group; 1977. p. xi, 516 p.
Nava-Ocampo AA, Koren G. Human teratogens and evidence-based teratogen risk counseling: the Motherisk approach. Clin Obstet Gynecol. 2007;50(1):123–31. Epub 2007/02/17.
Newman CG. Teratogen update: clinical aspects of thalidomide embryopathy—a continuing preoccupation. Teratology. 1985;32(1):133–44. Epub 1985/08/01.
Smithells RW. Defects and disabilities of thalidomide children. Br Med J. 1973;1(5848):269–72. Epub 1973/02/03.
Koren G, Bologa M, Long D, Feldman Y, Shear NH. Perception of teratogenic risk by pregnant women exposed to drugs and chemicals during the first trimester. Am J Obstet Gynecol. 1989;160(5 Pt 1):1190–4. Epub 1989/05/01.
Walfisch A, Sermer C, Matok I, Einarson A, Koren G. Perception of teratogenic risk and the rated likelihood of pregnancy termination: association with maternal depression. Can J Psychiatry. 2011;56(12):761–7. Epub 2011/12/14.
Neutel CI, Johansen HL. Measuring drug effectiveness by default: the case of Bendectin. Can J Public Health. 1995;86(1):66–70. Epub 1995/01/01.
Trichopoulos D, Zavitsanos X, Koutis C, Drogari P, Proukakis C, Petridou E. The victims of chernobyl in Greece: induced abortions after the accident. Br Med J (Clin Res Ed). 1987;295(6606):1100. Epub 1987/10/31
Ketchum LE. Lessons of Chernobyl: SNM members try to decontaminate world threatened by fallout. Part II. J Nucl Med. 1987;28(6):933–42. Epub 1987/06/01.
Andrade SE, Gurwitz JH, Davis RL, Chan KA, Finkelstein JA, Fortman K, et al. Prescription drug use in pregnancy. Am J Obstet Gynecol. 2004;191(2):398–407. Epub 2004/09/03.
Engeland A, Bramness JG, Daltveit AK, Ronning M, Skurtveit S, Furu K. Prescription drug use among fathers and mothers before and during pregnancy. A population-based cohort study of 106,000 pregnancies in Norway 2004-2006. Br J Clin Pharmacol. 2008;65(5):653–60. Epub 2008/02/26.
Kutscher AH, Zegarelli EV, Tovell HM, Hochberg B, Hauptman J. Discoloration of deciduous teeth induced by administration of tetracycline antepartum. Am J Obstet Gynecol. 1966;96(2):291–2. Epub 1966/09/15.
Hendricks SK, Smith JR, Moore DE, Brown ZA. Oligohydramnios associated with prostaglandin synthetase inhibitors in preterm labour. Br J Obstet Gynaecol. 1990;97(4):312–6. Epub 1990/04/01.
Levin DL. Effects of inhibition of prostaglandin synthesis on fetal development, oxygenation, and the fetal circulation. Semin Perinatol. 1980;4(1):35–44. Epub 1980/01/01.
Cunniff C, Jones KL, Phillipson J, Benirschke K, Short S, Wujek J. Oligohydramnios sequence and renal tubular malformation associated with maternal enalapril use. Am J Obstet Gynecol. 1990;162(1):187–9. Epub 1990/01/01.
Chudley AE, Conry J, Cook JL, Loock C, Rosales T, LeBlanc N. Fetal alcohol spectrum disorder: Canadian guidelines for diagnosis. CMAJ Can Med Assoc J. 2005;172(5 Suppl):S1–S21. Epub 2005/03/02.
Graham JM Jr, Hanson JW, Darby BL, Barr HM, Streissguth AP. Independent dysmorphology evaluations at birth and 4 years of age for children exposed to varying amounts of alcohol in utero. Pediatrics. 1988;81(6):772–8. Epub 1988/06/01.
Mills JL, Graubard BI. Is moderate drinking during pregnancy associated with an increased risk for malformations? Pediatrics. 1987;80(3):309–14. Epub 1987/09/01.
Sampson PD, Streissguth AP, Bookstein FL, Little RE, Clarren SK, Dehaene P, et al. Incidence of fetal alcohol syndrome and prevalence of alcohol-related neurodevelopmental disorder. Teratology. 1997;56(5):317–26. Epub 1998/02/06.
Meyer KA, Werler MM, Hayes C, Mitchell AA. Low maternal alcohol consumption during pregnancy and oral clefts in offspring: the Slone Birth Defects Study. Birth Defects Res A Clin Mol Teratol. 2003;67(7):509–14. Epub 2003/10/21.
Hyoun SC, Obican SG, Scialli AR. Teratogen update: methotrexate. Birth Defects Res A Clin Mol Teratol. 2012;94(4):187–207. Epub 2012/03/22.
Thiersch JB. Therapeutic abortions with a folic acid antagonist, 4-aminopteroylglutamic acid (4-amino P.G.A) administered by the oral route. Am J Obstet Gynecol. 1952;63(6):1298–304. Epub 1952/06/01.
Feldkamp M, Carey JC. Clinical teratology counseling and consultation case report: low dose methotrexate exposure in the early weeks of pregnancy. Teratology. 1993;47(6):533–9. Epub 1993/06/01.
Warkany J. Aminopterin and methotrexate: folic acid deficiency. Teratology. 1978;17(3):353–7. Epub 1978/06/01.
Del Campo M, Kosaki K, Bennett FC, Jones KL. Developmental delay in fetal aminopterin/methotrexate syndrome. Teratology. 1999;60(1):10–2. Epub 1999/07/21.
Enato E, Moretti M, Koren G. The fetal safety of benzodiazepines: an updated meta-analysis. J Obstet Gynaecol Can. 2011;33(1):46–8. Epub 2011/01/29.
Dolovich LR, Addis A, Vaillancourt JM, Power JD, Koren G, Einarson TR. Benzodiazepine use in pregnancy and major malformations or oral cleft: meta-analysis of cohort and case-control studies. BMJ. 1998;317(7162):839–43. Epub 1998/09/25.
Bergman U, Rosa FW, Baum C, Wiholm BE, Faich GA. Effects of exposure to benzodiazepine during fetal life. Lancet. 1992;340(8821):694–6. Epub 1992/09/19.
Kaaja E, Kaaja R, Hiilesmaa V. Major malformations in offspring of women with epilepsy. Neurology. 2003;60(4):575–9. Epub 2003/02/26.
Artama M, Auvinen A, Raudaskoski T, Isojarvi I, Isojarvi J. Antiepileptic drug use of women with epilepsy and congenital malformations in offspring. Neurology. 2005;64(11):1874–8. Epub 2005/06/16.
Morrow J, Russell A, Guthrie E, Parsons L, Robertson I, Waddell R, et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry. 2006;77(2):193–8. Epub 2005/09/15.
Wide K, Winbladh B, Kallen B. Major malformations in infants exposed to antiepileptic drugs in utero, with emphasis on carbamazepine and valproic acid: a nation-wide, population-based register study. Acta Paediatr. 2004;93(2):174–6. Epub 2004/03/30.
Meador KJ, Baker GA, Finnell RH, Kalayjian LA, Liporace JD, Loring DW, et al. In utero antiepileptic drug exposure: fetal death and malformations. Neurology. 2006;67(3):407–12. Epub 2006/08/09.
Jentink J, Dolk H, Loane MA, Morris JK, Wellesley D, Garne E, et al. Intrauterine exposure to carbamazepine and specific congenital malformations: systematic review and case-control study. BMJ. 2010;341:c6581. Epub 2010/12/04.
Tomson T, Battino D, Bonizzoni E, Craig J, Lindhout D, Perucca E, et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurol. 2018;17(6):530–8. Epub 2018/04/24.
Koren G, Sharav T, Pastuszak A, Garrettson LK, Hill K, Samson I, et al. A multicenter, prospective study of fetal outcome following accidental carbon monoxide poisoning in pregnancy. Reprod Toxicol. 1991;5(5):397–403. Epub 1991/01/01.
Dadvand P, Rankin J, Rushton S, Pless-Mulloli T. Ambient air pollution and congenital heart disease: a register-based study. Environ Res. 2011;111(3):435–41. Epub 2011/02/19.
Ritz B, Yu F, Fruin S, Chapa G, Shaw GM, Harris JA. Ambient air pollution and risk of birth defects in Southern California. Am J Epidemiol. 2002;155(1):17–25. Epub 2002/01/05.
Chavez GF, Mulinare J, Cordero JF. Maternal cocaine use during early pregnancy as a risk factor for congenital urogenital anomalies. JAMA. 1989;262(6):795–8. Epub 1989/08/11.
Frank DA, Zuckerman BS, Amaro H, Aboagye K, Bauchner H, Cabral H, et al. Cocaine use during pregnancy: prevalence and correlates. Pediatrics. 1988;82(6):888–95. Epub 1988/12/01.
Bingol N, Fuchs M, Diaz V, Stone RK, Gromisch DS. Teratogenicity of cocaine in humans. J Pediatr. 1987;110(1):93–6. Epub 1987/01/01.
Nulman I, Rovet J, Altmann D, Bradley C, Einarson T, Koren G. Neurodevelopment of adopted children exposed in utero to cocaine. CMAJ Can Med Assoc J. 1994;151(11):1591–7. Epub 1994/12/01.
Kliegman RM, Madura D, Kiwi R, Eisenberg I, Yamashita T. Relation of maternal cocaine use to the risks of prematurity and low birth weight. J Pediatr. 1994;124(5 Pt 1):751–6. Epub 1994/05/01.
Chasnoff IJ, Burns WJ, Schnoll SH, Burns KA. Cocaine use in pregnancy. N Engl J Med. 1985;313(11):666–9. Epub 1985/09/12.
Rodriguez-Pinilla E, Martinez-Frias ML. Corticosteroids during pregnancy and oral clefts: a case-control study. Teratology. 1998;58(1):2–5. Epub 1998/08/12.
Robert E, Vollset SE, Botto L, Lancaster PA, Merlob P, Mastroiacovo P, et al. Malformation surveillance and maternal drug exposure: the MADRE project. Int J Risk Saf Med. 1994;6(2):75–118. Epub 1994/01/01.
Czeizel AE, Rockenbauer M. Population-based case-control study of teratogenic potential of corticosteroids. Teratology. 1997;56(5):335–40. Epub 1998/02/06.
Fraser FC, Sajoo A. Teratogenic potential of corticosteroids in humans. Teratology. 1995;51(1):45–6. Epub 1995/01/01.
Carmichael SL, Shaw GM. Maternal corticosteroid use and risk of selected congenital anomalies. Am J Med Genet. 1999;86(3):242–4. Epub 1999/09/14.
Park-Wyllie L, Mazzotta P, Pastuszak A, Moretti ME, Beique L, Hunnisett L, et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology. 2000;62(6):385–92. Epub 2000/11/25.
Rayburn WF. Glucocorticoid therapy for rheumatic diseases: maternal, fetal, and breast-feeding considerations. Am J Reprod Immunol. 1992;28(3-4):138–40. Epub 1992/10/01.
Orr JW Jr, Shingleton HM, Gore H, Austin JM Jr, Hatch KD, Soong SJ. Cervical intraepithelial neoplasia associated with exposure to diethylstilbestrol in utero: a clinical and pathologic study. Obstet Gynecol. 1981;58(1):75–82. Epub 1981/07/01.
Barnes AB, Colton T, Gundersen J, Noller KL, Tilley BC, Strama T, et al. Fertility and outcome of pregnancy in women exposed in utero to diethylstilbestrol. N Engl J Med. 1980;302(11):609–13. Epub 1980/03/13.
Munk-Olsen T, Liu X, Viktorin A, Brown HK, Di Florio A, D’Onofrio BM, et al. Maternal and infant outcomes associated with lithium use in pregnancy: an international collaborative meta-analysis of six cohort studies. Lancet Psychiatry. 2018;5(8):644–52. Epub 2018/06/23.
Diav-Citrin O, Shechtman S, Tahover E, Finkel-Pekarsky V, Arnon J, Kennedy D, et al. Pregnancy outcome following in utero exposure to lithium: a prospective, comparative, observational study. Am J Psychiatry. 2014;171(7):785–94. Epub 2014/05/02.
Cohen LS, Friedman JM, Jefferson JW, Johnson EM, Weiner ML. A reevaluation of risk of in utero exposure to lithium. JAMA. 1994;271(2):146–50. Epub 1994/01/12.
Jacobson SJ, Jones K, Johnson K, Ceolin L, Kaur P, Sahn D, et al. Prospective multicentre study of pregnancy outcome after lithium exposure during first trimester. Lancet. 1992;339(8792):530–3. Epub 1992/02/29.
Weber-Schoendorfer C, Chambers C, Wacker E, Beghin D, Bernard N, Shechtman S, et al. Pregnancy outcome after methotrexate treatment for rheumatic disease prior to or during early pregnancy: a prospective multicenter cohort study. Arthritis Rheumatol. 2014;66(5):1101–10. Epub 2014/01/29.
Chapa JB, Hibbard JU, Weber EM, Abramowicz JS, Verp MS. Prenatal diagnosis of methotrexate embryopathy. Obstet Gynecol. 2003;101(5 Pt 2):1104–7. Epub 2003/05/10.
Adam MP, Manning MA, Beck AE, Kwan A, Enns GM, Clericuzio C, et al. Methotrexate/misoprostol embryopathy: report of four cases resulting from failed medical abortion. Am J Med Genet A. 2003;123A(1):72–8. Epub 2003/10/14.
Yedlinsky NT, Morgan FC, Whitecar PW. Anomalies associated with failed methotrexate and misoprostol termination. Obstet Gynecol. 2005;105(5 Pt 2):1203–5. Epub 2005/05/03.
Usta IM, Nassar AH, Yunis KA, Abu-Musa AA. Methotrexate embryopathy after therapy for misdiagnosed ectopic pregnancy. Int J Gynaecol Obstet. 2007;99(3):253–5. Epub 2007/09/25.
Wheeler M, O’Meara P, Stanford M. Fetal methotrexate and misoprostol exposure: the past revisited. Teratology. 2002;66(2):73–6. Epub 2002/09/05.
Poggi SH, Ghidini A. Importance of timing of gestational exposure to methotrexate for its teratogenic effects when used in setting of misdiagnosis of ectopic pregnancy. Fertil Steril. 2011;96(3):669–71. Epub 2011/07/08.
Harada M. Congenital Minamata disease: intrauterine methylmercury poisoning. Teratology. 1978;18(2):285–8. Epub 1978/10/01.
Amin-Zaki L, Majeed MA, Greenwood MR, Elhassani SB, Clarkson TW, Doherty RA. Methylmercury poisoning in the Iraqi suckling infant: a longitudinal study over five years. J Appl Toxicol. 1981;1(4):210–4. Epub 1981/08/01.
Marsh DO, Myers GJ, Clarkson TW, Amin-Zaki L, Tikriti S, Majeed MA. Fetal methylmercury poisoning: clinical and toxicological data on 29 cases. Ann Neurol. 1980;7(4):348–53. Epub 1980/04/01.
Merlob P, Stahl B, Klinger G. Tetrada of the possible mycophenolate mofetil embryopathy: a review. Reprod Toxicol. 2009;28(1):105–8. Epub 2009/06/06.
Sifontis NM, Coscia LA, Constantinescu S, Lavelanet AF, Moritz MJ, Armenti VT. Pregnancy outcomes in solid organ transplant recipients with exposure to mycophenolate mofetil or sirolimus. Transplantation. 2006;82(12):1698–702. Epub 2007/01/02.
Hoeltzenbein M, Elefant E, Vial T, Finkel-Pekarsky V, Stephens S, Clementi M, et al. Teratogenicity of mycophenolate confirmed in a prospective study of the European Network of Teratology Information Services. Am J Med Genet A. 2012;158A(3):588–96. Epub 2012/02/10.
Yamashita F, Hayashi M. Fetal PCB syndrome: clinical features, intrauterine growth retardation and possible alteration in calcium metabolism. Environ Health Perspect. 1985;59:41–5. Epub 1985/02/01.
Rosa FW. Teratogen update: penicillamine. Teratology. 1986;33(1):127–31. Epub 1986/02/01.
Hanukoglu A, Curiel B, Berkowitz D, Levine A, Sack J, Lorberboym M. Hypothyroidism and dyshormonogenesis induced by D-penicillamine in children with Wilson’s disease and healthy infants born to a mother with Wilson’s disease. J Pediatr. 2008;153(6):864–6. Epub 2008/11/19.
Bertollini R, Kallen B, Mastroiacovo P, Robert E. Anticonvulsant drugs in monotherapy. Effect on the fetus. Eur J Epidemiol. 1987;3(2):164–71. Epub 1987/06/01.
Kjaer D, Horvath-Puho E, Christensen J, Vestergaard M, Czeizel AE, Sorensen HT, et al. Use of phenytoin, phenobarbital, or diazepam during pregnancy and risk of congenital abnormalities: a case-time-control study. Pharmacoepidemiol Drug Saf. 2007;16(2):181–8. Epub 2006/08/31.
Arpino C, Brescianini S, Robert E, Castilla EE, Cocchi G, Cornel MC, et al. Teratogenic effects of antiepileptic drugs: use of an International Database on Malformations and Drug Exposure (MADRE). Epilepsia. 2000;41(11):1436–43. Epub 2000/11/15.
Waters CH, Belai Y, Gott PS, Shen P, De Giorgio CM. Outcomes of pregnancy associated with antiepileptic drugs. Arch Neurol. 1994;51(3):250–3. Epub 1994/03/01.
Smith DW. Teratogenicity of anticonvulsive medications. Am J Dis Child. 1977;131(12):1337–9. Epub 1977/12/01.
Harden CL, Meador KJ, Pennell PB, Hauser WA, Gronseth GS, French JA, et al. Management issues for women with epilepsy-Focus on pregnancy (an evidence-based review): II. Teratogenesis and perinatal outcomes: Report of the Quality Standards Subcommittee and Therapeutics and Technology Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Epilepsia. 2009;50(5):1237–46. Epub 2009/06/10.
Berard A, Azoulay L, Koren G, Blais L, Perreault S, Oraichi D. Isotretinoin, pregnancies, abortions and birth defects: a population-based perspective. Br J Clin Pharmacol. 2007;63(2):196–205. Epub 2007/01/12.
Lammer EJ, Chen DT, Hoar RM, Agnish ND, Benke PJ, Braun JT, et al. Retinoic acid embryopathy. N Engl J Med. 1985;313(14):837–41. Epub 1985/10/03.
Vargesson N. Thalidomide-induced teratogenesis: history and mechanisms. Birth Defects Res C Embryo Today. 2015;105(2):140–56. Epub 2015/06/06.
Samren EB, van Duijn CM, Koch S, Hiilesmaa VK, Klepel H, Bardy AH, et al. Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy. Epilepsia. 1997;38(9):981–90. Epub 1998/05/14.
Valproic acid and spina bifida: a preliminary report—France. MMWR Morb Mortal Wkly Rep. 1982;31(42):565–6. Epub 1982/10/29.
Valproate: a new cause of birth defects—report from Italy and follow-up from France. MMWR Morb Mortal Wkly Rep. 1983;32(33):438–9. Epub 1983/08/26.
Jentink J, Loane MA, Dolk H, Barisic I, Garne E, Morris JK, et al. Valproic acid monotherapy in pregnancy and major congenital malformations. N Engl J Med. 2010;362(23):2185–93. Epub 2010/06/19.
Hall JG, Pauli RM, Wilson KM. Maternal and fetal sequelae of anticoagulation during pregnancy. Am J Med. 1980;68(1):122–40. Epub 1980/01/01.
Iturbe-Alessio I, Fonseca MC, Mutchinik O, Santos MA, Zajarias A, Salazar E. Risks of anticoagulant therapy in pregnant women with artificial heart valves. N Engl J Med. 1986;315(22):1390–3. Epub 1986/11/27.
Ville Y, Jenkins E, Shearer MJ, Hemley H, Vasey DP, Layton M, et al. Fetal intraventricular haemorrhage and maternal warfarin. Lancet. 1993;341(8854):1211. Epub 1993/05/08.
Chan WS, Anand S, Ginsberg JS. Anticoagulation of pregnant women with mechanical heart valves: a systematic review of the literature. Arch Intern Med. 2000;160(2):191–6. Epub 2000/01/27.
Raynor BD. Cytomegalovirus infection in pregnancy. Semin Perinatol. 1993;17(6):394–402. Epub 1993/12/01.
Leruez-Ville M, Ville Y. Fetal cytomegalovirus infection. Best Pract Res Clin Obstet Gynaecol. 2017;38:97–107. Epub 2016/12/08.
Brown HL, Abernathy MP. Cytomegalovirus infection. Semin Perinatol. 1998;22(4):260–6. Epub 1998/09/17.
Hedrick J. The effects of human parvovirus B19 and cytomegalovirus during pregnancy. J Perinat Neonatal Nurs. 1996;10(2):30–9. Epub 1996/09/01.
Bodeus M, Hubinont C, Goubau P. Increased risk of cytomegalovirus transmission in utero during late gestation. Obstet Gynecol. 1999;93(5 Pt 1):658–60. Epub 2000/07/27.
Fowler KB, Stagno S, Pass RF, Britt WJ, Boll TJ, Alford CA. The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. N Engl J Med. 1992;326(10):663–7. Epub 1992/03/05.
Malinger G, Lev D, Zahalka N, Ben Aroia Z, Watemberg N, Kidron D, et al. Fetal cytomegalovirus infection of the brain: the spectrum of sonographic findings. AJNR Am J Neuroradiol. 2003;24(1):28–32. Epub 2003/01/21.
Gratacos E, Torres PJ, Vidal J, Antolin E, Costa J. Jimenez de Anta MT, et al. The incidence of human parvovirus B19 infection during pregnancy and its impact on perinatal outcome. J Infect Dis. 1995;171(5):1360–3. Epub 1995/05/01.
Prospective study of human parvovirus (B19) infection in pregnancy. Public Health Laboratory Service Working Party on Fifth Disease. BMJ. 1990;300(6733):1166–70. Epub 1990/05/05.
Markenson GR, Yancey MK. Parvovirus B19 infections in pregnancy. Semin Perinatol. 1998;22(4):309–17. Epub 1998/09/17
Control and prevention of rubella: evaluation and management of suspected outbreaks, rubella in pregnant women, and surveillance for congenital rubella syndrome. MMWR Recomm Rep. 2001;50(RR-12):1–23. Epub 2001/07/28.
Reef SE, Plotkin S, Cordero JF, Katz M, Cooper L, Schwartz B, et al. Preparing for elimination of congenital Rubella syndrome (CRS): summary of a workshop on CRS elimination in the United States. Clin Infect Dis. 2000;31(1):85–95. Epub 2000/07/29.
Webster WS. Teratogen update: congenital rubella. Teratology. 1998;58(1):13–23. Epub 1998/08/12.
McIntosh ED, Menser MA. A fifty-year follow-up of congenital rubella. Lancet. 1992;340(8816):414–5. Epub 1992/08/15.
Dunn D, Wallon M, Peyron F, Petersen E, Peckham C, Gilbert R. Mother-to-child transmission of toxoplasmosis: risk estimates for clinical counselling. Lancet. 1999;353(9167):1829–33. Epub 1999/06/08.
McAuley J, Boyer KM, Patel D, Mets M, Swisher C, Roizen N, et al. Early and longitudinal evaluations of treated infants and children and untreated historical patients with congenital toxoplasmosis: the Chicago Collaborative Treatment Trial. Clin Infect Dis. 1994;18(1):38–72. Epub 1994/01/01.
Koppe JG, Loewer-Sieger DH, de Roever-Bonnet H. Results of 20-year follow-up of congenital toxoplasmosis. Lancet. 1986;1(8475):254–6. Epub 1986/02/01.
Wilson CB, Remington JS, Stagno S, Reynolds DW. Development of adverse sequelae in children born with subclinical congenital Toxoplasma infection. Pediatrics. 1980;66(5):767–74. Epub 1980/11/01.
Goldenberg RL, Thompson C. The infectious origins of stillbirth. Am J Obstet Gynecol. 2003;189(3):861–73. Epub 2003/10/04.
Saxoni F, Lapaanis P, Pantelakis SN. Congenital syphilis: a description of 18 cases and re-examination of an old but ever-present disease. Clin Pediatr. 1967;6(12):687–91. Epub 1967/12/01.
Whitaker JA, Sartain P, Shaheedy M. Hematological aspects of congenital syphilis. J Pediatr. 1965;66:629–36. Epub 1965/03/01.
Smith CK, Arvin AM. Varicella in the fetus and newborn. Semin Fetal Neonatal Med. 2009;14(4):209–17. Epub 2008/12/23.
Ahn KH, Park YJ, Hong SC, Lee EH, Lee JS, Oh MJ, et al. Congenital varicella syndrome: a systematic review. J Obstet Gynaecol. 2016;36(5):563–6. Epub 2016/03/12.
Tan MP, Koren G. Chickenpox in pregnancy: revisited. Reprod Toxicol. 2006;21(4):410–20. Epub 2005/06/28.
Sanchez MA, Bello-Munoz JC, Cebrecos I, Sanz TH, Martinez JS, Moratonas EC, et al. The prevalence of congenital varicella syndrome after a maternal infection, but before 20 weeks of pregnancy: a prospective cohort study. J Maternal Fetal Neonatal Med. 2011;24(2):341–7. Epub 2010/07/31.
Harger JH, Ernest JM, Thurnau GR, Moawad A, Thom E, Landon MB, et al. Frequency of congenital varicella syndrome in a prospective cohort of 347 pregnant women. Obstet Gynecol. 2002;100(2):260–5. Epub 2002/08/02.
Gilbert GL. Chickenpox during pregnancy. BMJ. 1993;306(6885):1079–80. Epub 1993/04/24.
Leone T, Coast E, Correa S, Wenham C. Web-based searching for abortion information during health emergencies: a case study of Brazil during the 2015/2016 Zika outbreak. Sex Reprod Health Matters. 2021;29(1):1883804. Epub 2021/02/19.
Sarno M, Sacramento GA, Khouri R, do Rosario MS, Costa F, Archanjo G, et al. Zika virus infection and stillbirths: a case of hydrops fetalis, hydranencephaly and fetal demise. PLoS Negl Trop Dis. 2016;10(2):e0004517. Epub 2016/02/26.
van der Eijk AA, van Genderen PJ, Verdijk RM, Reusken CB, Mogling R, van Kampen JJ, et al. Miscarriage associated with Zika virus infection. N Engl J Med. 2016;375(10):1002–4. Epub 2016/07/28.
Mlakar J, Korva M, Tul N, Popovic M, Poljsak-Prijatelj M, Mraz J, et al. Zika virus associated with microcephaly. N Engl J Med. 2016;374(10):951–8. Epub 2016/02/11.
Cauchemez S, Besnard M, Bompard P, Dub T, Guillemette-Artur P, Eyrolle-Guignot D, et al. Association between Zika virus and microcephaly in French Polynesia, 2013-15: a retrospective study. Lancet. 2016;387(10033):2125–32. Epub 2016/03/20.
de Araujo TVB, Rodrigues LC, de Alencar Ximenes RA, de Barros M-FD, Montarroyos UR, de Melo APL, et al. Association between Zika virus infection and microcephaly in Brazil, January to May, 2016: preliminary report of a case-control study. Lancet Infect Dis. 2016;16(12):1356–63. Epub 2016/09/20.
Moore CA, Staples JE, Dobyns WB, Pessoa A, Ventura CV, Fonseca EB, et al. Characterizing the pattern of anomalies in congenital Zika syndrome for pediatric clinicians. JAMA Pediatr. 2017;171(3):288–95. Epub 2016/11/05.
Del Campo M, Feitosa IM, Ribeiro EM, Horovitz DD, Pessoa AL, Franca GV, et al. The phenotypic spectrum of congenital Zika syndrome. Am J Med Genet A. 2017;173(4):841–57. Epub 2017/03/23.
Hoen B, Schaub B, Funk AL, Ardillon V, Boullard M, Cabie A, et al. Pregnancy outcomes after ZIKV infection in French Territories in the Americas. N Engl J Med. 2018;378(11):985–94. Epub 2018/03/15.
Brasil P, Pereira JP Jr, Moreira ME, Ribeiro Nogueira RM, Damasceno L, Wakimoto M, et al. Zika Virus Infection in Pregnant Women in Rio de Janeiro. N Engl J Med. 2016;375(24):2321–34. Epub 2016/03/05.
Souza JP, Meio M, de Andrade LM, Figueiredo MR, Gomes Junior SC, Pereira Junior JP, et al. Adverse fetal and neonatal outcomes in pregnancies with confirmed Zika Virus infection in Rio de Janeiro, Brazil: a cohort study. PLoS Negl Trop Dis. 2021;15(1):e0008893. Epub 2021/01/05.
DeSisto CL, Wallace B, Simeone RM, Polen K, Ko JY, Meaney-Delman D, et al. Risk for stillbirth among women with and without COVID-19 at delivery hospitalization—United States, March 2020-September 2021. MMWR Morb Mortal Wkly Rep. 2021;70(47):1640–5. Epub 2021/11/25.
Bellos I, Pandita A, Panza R. Maternal and perinatal outcomes in pregnant women infected by SARS-CoV-2: A meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2021;256:194–204. Epub 2020/11/28.
Juan J, Gil MM, Rong Z, Zhang Y, Yang H, Poon LC. Effect of coronavirus disease 2019 (COVID-19) on maternal, perinatal and neonatal outcome: systematic review. Ultrasound Obstet Gynecol. 2020;56(1):15–27. Epub 2020/05/21.
Schwartz DA, Baldewijns M, Benachi A, Bugatti M, Collins RRJ, De Luca D, et al. Chronic histiocytic intervillositis with trophoblast necrosis is a risk factor associated with placental infection from coronavirus disease 2019 (COVID-19) and intrauterine maternal-fetal severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission in live-born and stillborn infants. Arch Pathol Lab Med. 2021;145(5):517–28. Epub 2021/01/05.
Ganor Paz Y, Shiloh S, Brosh-Nissimov T, Grupel D, Sorek N, Kustin T, et al. The association between SARS-CoV-2 infection and late pregnancy loss. Int J Gynaecol Obstet. 2021. Epub 2021/11/16.
Dekaban AS. Abnormalities in children exposed to x-radiation during various stages of gestation: tentative timetable of radiation injury to the human fetus. I. J Nucl Med. 1968;9(9):471–7. Epub 1968/09/01.
Miller RW. Delayed radiation effects in atomic-bomb survivors. Major observations by the Atomic Bomb Casualty Commission are evaluated. Science. 1969;166(3905):569–74. Epub 1969/10/31.
Plummer G. Anomalies occurring in children exposed in utero to the atomic bomb in Hiroshima. Pediatrics. 1952;10(6):687–93. Epub 1952/12/01.
Wood JW, Johnson KG, Omori Y. In utero exposure to the Hiroshima atomic bomb. An evaluation of head size and mental retardation: twenty years later. Pediatrics. 1967;39(3):385–92. Epub 1967/03/01.
Jankowski CB. Radiation and pregnancy. Putting the risks in proportion. Am J Nurs. 1986;86(3):260–5. Epub 1986/03/01.
Lione A. Ionizing radiation and human reproduction. Reprod Toxicol. 1987;1(1):3–16. Epub 1987/01/01.
Russell LB, Russell WL. An analysis of the changing radiation response of the developing mouse embryo. J Cell Physiol Suppl. 1954;43(Suppl. 1):103–49. Epub 1954/05/01.
Rowley KA, Hill SJ, Watkins RA, Moores BM. An investigation into the levels of radiation exposure in diagnostic examinations involving fluoroscopy. Br J Radiol. 1987;60(710):167–73. Epub 1987/02/01.
Koren G. Medication safety in pregnancy and breastfeeding. New York: McGraw-Hill, Health Professions Division; 2007. p. xv, 623 p.
Hellman LM, Duffus GM, Donald I, Sunden B. Safety of diagnostic ultrasound in obstetrics. Lancet. 1970;1(7657):1133–4. Epub 1970/05/30.
Scheidt PC, Stanley F, Bryla DA. One-year follow-up of infants exposed to ultrasound in utero. Am J Obstet Gynecol. 1978;131(7):743–8. Epub 1978/08/01.
Stark CR, Orleans M, Haverkamp AD, Murphy J. Short- and long-term risks after exposure to diagnostic ultrasound in utero. Obstet Gynecol. 1984;63(2):194–200. Epub 1984/02/01.
Wilson MK. Obstetric ultrasound and childhood malignancies. Radiography. 1985;51(600):319–20. Epub 1985/11/01.
Smith DP, Graham JB, Prystowsky JB, Dalkin BL, Nemcek AA Jr. The effects of ultrasound-guided shock waves during early pregnancy in Sprague-Dawley rats. J Urol. 1992;147(1):231–4. Epub 1992/01/11.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Barzilay, E., Koren, G. (2023). Elements of Teratology. In: Abramowicz, J.S., Longman, R.E. (eds) First-Trimester Ultrasound. Springer, Cham. https://doi.org/10.1007/978-3-031-24133-8_6
Download citation
DOI: https://doi.org/10.1007/978-3-031-24133-8_6
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-24132-1
Online ISBN: 978-3-031-24133-8
eBook Packages: MedicineMedicine (R0)